Benzodiazepine use in Sao Paulo, Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/172921 |
Resumo: | OBJECTIVES: To report the prevalence and factors associated with the use of benzodiazepines in the general population and those with a mental health condition in the metropolitan area of Sa˜o Paulo, Brazil. METHODS: 5,037 individuals from the Sao Paulo Megacity Mental Health Survey data were interviewed using the Composite International Diagnostic Interview, designed to generate DSM-IV diagnoses. Additionally, participants were asked if they had taken any medication in the previous 12 months for the treatment of any mental health condition. RESULTS: The prevalence of benzodiazepine use ranged from 3.6% in the general population to 7.8% among subjects with a mental health condition. Benzodiazepine use was more prevalent in subjects that had been diagnosed with a mood disorder as opposed to an anxiety disorder (14.7% vs. 8.1%, respectively). Subjects that had been diagnosed with a panic disorder (33.7%) or bipolar I/II (23.3%) reported the highest use. Individuals aged X50 years (11.1%), those with two or more disorders (11.2%), those with moderate or severe disorders (10%), and those that used psychiatric services (29.8%) also reported higher use. CONCLUSION: These findings give an overview of the use of benzodiazepines in the general population, which will be useful in the public health domain. Benzodiazepine use was higher in those with a mental health condition, with people that had a mood disorder being the most vulnerable. Furthermore, females and the elderly had high benzodiazepine use, so careful management in these groups is required. |
id |
USP-19_3bb681cb08b969a649cecccf37d32efa |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/172921 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Benzodiazepine use in Sao Paulo, BrazilPsychiatryPharmacyPsychotropic DrugsHypnotics and SedativesBenzodiazepinesOBJECTIVES: To report the prevalence and factors associated with the use of benzodiazepines in the general population and those with a mental health condition in the metropolitan area of Sa˜o Paulo, Brazil. METHODS: 5,037 individuals from the Sao Paulo Megacity Mental Health Survey data were interviewed using the Composite International Diagnostic Interview, designed to generate DSM-IV diagnoses. Additionally, participants were asked if they had taken any medication in the previous 12 months for the treatment of any mental health condition. RESULTS: The prevalence of benzodiazepine use ranged from 3.6% in the general population to 7.8% among subjects with a mental health condition. Benzodiazepine use was more prevalent in subjects that had been diagnosed with a mood disorder as opposed to an anxiety disorder (14.7% vs. 8.1%, respectively). Subjects that had been diagnosed with a panic disorder (33.7%) or bipolar I/II (23.3%) reported the highest use. Individuals aged X50 years (11.1%), those with two or more disorders (11.2%), those with moderate or severe disorders (10%), and those that used psychiatric services (29.8%) also reported higher use. CONCLUSION: These findings give an overview of the use of benzodiazepines in the general population, which will be useful in the public health domain. Benzodiazepine use was higher in those with a mental health condition, with people that had a mood disorder being the most vulnerable. Furthermore, females and the elderly had high benzodiazepine use, so careful management in these groups is required.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2020-07-27info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/xmlhttps://www.revistas.usp.br/clinics/article/view/17292110.6061/clinics/2020/e1610Clinics; Vol. 75 (2020); e1610Clinics; v. 75 (2020); e1610Clinics; Vol. 75 (2020); e16101980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/172921/162322https://www.revistas.usp.br/clinics/article/view/172921/162323Copyright (c) 2020 Clinicsinfo:eu-repo/semantics/openAccessCampanha, Angela MariaRavagnani, BeatrizMilhoranc¸a, Igor AndréBernik, Márcio AntoniniViana, Maria CarmenWang, Yuan-PangAndrade, Laura Helena2020-07-27T20:17:27Zoai:revistas.usp.br:article/172921Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2020-07-27T20:17:27Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Benzodiazepine use in Sao Paulo, Brazil |
title |
Benzodiazepine use in Sao Paulo, Brazil |
spellingShingle |
Benzodiazepine use in Sao Paulo, Brazil Campanha, Angela Maria Psychiatry Pharmacy Psychotropic Drugs Hypnotics and Sedatives Benzodiazepines |
title_short |
Benzodiazepine use in Sao Paulo, Brazil |
title_full |
Benzodiazepine use in Sao Paulo, Brazil |
title_fullStr |
Benzodiazepine use in Sao Paulo, Brazil |
title_full_unstemmed |
Benzodiazepine use in Sao Paulo, Brazil |
title_sort |
Benzodiazepine use in Sao Paulo, Brazil |
author |
Campanha, Angela Maria |
author_facet |
Campanha, Angela Maria Ravagnani, Beatriz Milhoranc¸a, Igor André Bernik, Márcio Antonini Viana, Maria Carmen Wang, Yuan-Pang Andrade, Laura Helena |
author_role |
author |
author2 |
Ravagnani, Beatriz Milhoranc¸a, Igor André Bernik, Márcio Antonini Viana, Maria Carmen Wang, Yuan-Pang Andrade, Laura Helena |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Campanha, Angela Maria Ravagnani, Beatriz Milhoranc¸a, Igor André Bernik, Márcio Antonini Viana, Maria Carmen Wang, Yuan-Pang Andrade, Laura Helena |
dc.subject.por.fl_str_mv |
Psychiatry Pharmacy Psychotropic Drugs Hypnotics and Sedatives Benzodiazepines |
topic |
Psychiatry Pharmacy Psychotropic Drugs Hypnotics and Sedatives Benzodiazepines |
description |
OBJECTIVES: To report the prevalence and factors associated with the use of benzodiazepines in the general population and those with a mental health condition in the metropolitan area of Sa˜o Paulo, Brazil. METHODS: 5,037 individuals from the Sao Paulo Megacity Mental Health Survey data were interviewed using the Composite International Diagnostic Interview, designed to generate DSM-IV diagnoses. Additionally, participants were asked if they had taken any medication in the previous 12 months for the treatment of any mental health condition. RESULTS: The prevalence of benzodiazepine use ranged from 3.6% in the general population to 7.8% among subjects with a mental health condition. Benzodiazepine use was more prevalent in subjects that had been diagnosed with a mood disorder as opposed to an anxiety disorder (14.7% vs. 8.1%, respectively). Subjects that had been diagnosed with a panic disorder (33.7%) or bipolar I/II (23.3%) reported the highest use. Individuals aged X50 years (11.1%), those with two or more disorders (11.2%), those with moderate or severe disorders (10%), and those that used psychiatric services (29.8%) also reported higher use. CONCLUSION: These findings give an overview of the use of benzodiazepines in the general population, which will be useful in the public health domain. Benzodiazepine use was higher in those with a mental health condition, with people that had a mood disorder being the most vulnerable. Furthermore, females and the elderly had high benzodiazepine use, so careful management in these groups is required. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-07-27 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/172921 10.6061/clinics/2020/e1610 |
url |
https://www.revistas.usp.br/clinics/article/view/172921 |
identifier_str_mv |
10.6061/clinics/2020/e1610 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/172921/162322 https://www.revistas.usp.br/clinics/article/view/172921/162323 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2020 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/xml |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 75 (2020); e1610 Clinics; v. 75 (2020); e1610 Clinics; Vol. 75 (2020); e1610 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222765143293952 |